Epithelial Mesenchymal Transition: The crossroads between differentiation, tumorigenicity, invasion and cell death

S104 Cancer Sciences
Medical and Dental Sciences
Tuesday 8th July 2014 (13:00-14:00)
Download the date to your calendar (.ics file)

For further information please contact the seminar host, Dr Fedor  Berditchevski  E: F.Berditchevski@bham.ac.uk.  T: +44(0)121 414 2801 or Pauline Goddard E: P.N.Goddard@bham.ac.uk  T: +44(0)121 414 7144

Epithelial Mesenchymal Transition: The crossroads between differentiation, tumorigenicity, invasion and cell death

Dr Eugene Tulchinsky,Department of Cancer Studies and Molecular Medicine, University of Leicester.

Biography: Dr. Tulchisky graduated from the Moscow State University and was awarded PhD in Molecular Biology at the Engelhardt Institute of Russian Academy of Sciences. He was as a Post-doctoral Fellow at the Danish Cancer Society Research Center before setting up his Laboratory in Leicester.

Research interests: Epithelial mesenchymal transition (EMT), the generation of motile and invasive mesenchymal cells from epithelial sheets, is increasingly recognised as the mechanistic basis for metastatic conversion of tumour cells. In non-pathological conditions, EMT is essential for a number of steps in embryonic development and in wound healing. Dr. Tulchisky’s interests are in the area of the interaction between EMT and other critical pathways leading to oncogenic transformation, cell proliferation, senescence or death. The data from his laboratory show that different EMT programs may cooperate with classical oncogenic pathways in oncogenic transformation. They may or may not affect cell cycle progression, senescence and DNA damage-induced apoptosis. Dr.Tulchisky proposes that EMT programs determine such important cancer properties as altered sensitivity of disseminating cancers to different therapies or a phenomenon of dormant metastasis.

Selection of Recent Publications:

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E. Cancer Cell. 2013 Oct 14;24(4):466-80.  

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Sayan AE, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K, Edwards R, Pal R, Greaves P, Jariel-Encontre I, Piechaczyk M, Kriajevska M, Mellon JK, Dhillon AS, Tulchinsky E. Oncogene. 2012 Mar 22;31(12):1493-503

ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Browne G, Sayan AE, Tulchinsky E. Cell Cycle. 2010 Mar 1;9(5):886-91. Epub 2010 Mar 3. Review.

SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, Edwards R, Mayer NJ, Qazi H, Goyal S, Fernandez S, Straatman K, Jones GD, Bowman KJ, Colquhoun A, Mellon JK, Kriajevska M, Tulchinsky E. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14884-9.